{"id":"W3215508843","doi":"10.1093/neuonc/noab196.242","title":"CTNI-17. A PHASE 1 WITH DOSE EXPANSION/PHASE 2 STUDY OF SELINEXOR IN COMBINATION WITH STANDARD OF CARE THERAPY FOR NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA","year":2021,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Nuclear Structure and Function","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Temozolomide; Clinical endpoint; Medicine; Oncology; Bevacizumab; Phases of clinical research; Internal medicine; Radiation therapy; Clinical trial; Cancer research; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002342785,0.001984251,0.001878871,0.0008669131,0.0004144346,0.001309864,0.001566468,0.001679076,0.005012957],"category_scores_gemma":[0.0009458163,0.0007535191,0.001636268,0.0005503503,0.001239189,0.001081029,0.0004721394,0.003924406,0.001236384],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001376867,"about_ca_system_score_gemma":0.002833249,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001644565,"about_ca_topic_score_gemma":0.004551006,"domain_scores_codex":[0.9994098,0.0002749555,0.00002493599,0.00008810511,0.00007391341,0.0001283845],"domain_scores_gemma":[0.9994025,0.00005361975,0.0001269657,0.00005102783,0.00005526893,0.0003105148],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.624213,0.1381706,0.004583128,0.002287346,0.002395653,0.0004338896,0.0004586967,0.004445456,0.06274849,0.001151247,0.01325063,0.1458618],"study_design_scores_gemma":[0.5608692,0.4183609,0.004647576,0.00009771706,0.0005890609,0.000335247,0.00007642126,0.001242729,0.006868691,0.0004518387,0.006412935,0.00004782671],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9735109,0.00602896,0.001394121,0.001645254,0.0004487721,0.01047055,0.002859198,0.0003571273,0.003285205],"genre_scores_gemma":[0.9455624,0.008406726,0.007612101,0.003153436,0.0004089325,0.01779644,0.006669916,0.0001776272,0.01021232],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005012957,"threshold_uncertainty_score":0.01677001,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01334965007866061,"score_gpt":0.3127865269656032,"score_spread":0.2994368768869426,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}